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Abstract 
 
Purpose. To assess the clinical evidence, outcome and cost of off-label use of 
medicines in the hospital setting. 
Methods. A multicentric prospective cohort study of patients treated with off-label 
medicines was carried out in five tertiary hospitals from May 2011-May 2012. 
Information on clinical characteristics of patients, drugs, outcomes and costs was 
collected. Patients were followed up to six months and information was assessed by 
reviewing clinical records and interviewing physicians.  
Results. A total of 226 patients were included. The median [IQR] age of patients was 
46 (33-62) years; 59% were women. Patients had received a median of three 
previous treatments, and a lack of response was the main reason for off-label use 
(70.8%). A total of 232 off-label medicines were administered for 102 different 
indications. The most frequent medicines were rituximab (49; 21.1%), botulinum toxin 
(25; 10.7%) and omalizumab (14; 6.0%). In 117 (51.8%) cases the level of clinical 
evidence for their use was low. A partial clinical response was observed in 82 
patients (36.3%), complete response in 71 (31.4%) and stabilization in 11 (4.9%). A 
total of 58 (26.5%) patients had adverse effects, which in 11 (4.9%) were severe. The 
median (IQR) cost per patient was € 2,943.07 (541.9 – 5,872.54). 
Conclusions. There was a high variability of off-label medicines and indications. 
Although the clinical evidence of off-label medicines was often low, clinical response 
was observed in many patients with previous multiple treatment failure, but at the 
expense of some adverse effects and a high cost. Registers of patients would be 
helpful for clinical decisions, although clinical trials are needed. 
 
Keywords: Off-label use, drug therapy, efficiency, rituximab, omalizumab, botulinum 
toxin, pharmacy and therapeutics committees. 
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Introduction 
 
Off-label medicine use includes the prescription of a medicine for an indication, a 
route of administration, or a patient group that is not approved in the summary 
product characteristics [1]. The off-label use of medicines is a common and 
widespread clinical practice worldwide [2, 3]. However, the use of medicines outside 
the approved clinical indications may lead to several problems. Evidence on the use 
of these medicines in unapproved indications is often scarce, and doctors have little 
information on how to use them. In addition, off-label use of medicines can cause 
adverse effects and the risk may outweigh the potential benefits. Furthermore, ethical 
and legal issues related to the commercial promotion of off-label use of these 
medications have also been raised [4-6]. 
 
Since 2009 a new Spanish legislation regulates and classifies the availability of drug 
use in special situations: the use of medicines in unapproved conditions, the 
compassionate use of investigational medicines, and the use of medicines not 
marketed in the country [7]. Currently, only a doctor's report to justify the use of the 
off-label medicines, and the patient's informed consent is required. Nevertheless, the 
widespread use of these drugs may often increase spending on drugs, especially in 
the hospital setting. In order to avoid unwarranted risks and cost of drugs with limited 
data on their efficacy, the Catalan Health Service has put internal procedures in place 
[8]. This regulation states that the drug and therapeutics committees of each hospital 
needs to perform an evaluation of all cases of drug use in special situations, and the 
Medical Director  of each hospital must give individual authorisation for each patient . 
 
Several studies have evaluated the use of off-label medicines, but they have often 
focused on specific groups of drugs or medicines, such as anticancer drugs [9-11] or 
rituximab [12, 13], or on specific populations, such as children [14-17]. However, very 
few studies have evaluated the clinical outcomes of off-label medicines in terms of 
effectiveness and safety, as well as the associated costs [12, 18, 19]. The aim of our 
study was to assess the clinical and economic outcomes, and the clinical evidence 
for off-label use of medicines in the hospital setting.  
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Methods 
 
A prospective longitudinal study of patients treated with off-label drugs was carried 
out in five public hospitals belonging to the Catalan Institute of Health for a period of 
one year (from 19th May 2011 to 19th May 2012). Requests for drugs use in special 
situations, taking into account the current Spanish legislation, received in the 
pharmacy services of the hospitals during the study period were identified. All 
requests for off-label uses were included, and those for compassionate use of 
investigational drugs and for unauthorised drugs in Spain (if requested for conditions 
approved in other countries) were excluded. In addition, those for off-label drug use 
that were not authorised by hospital medical directors, those for which patient 
informed consent was not obtained, or those in whom medicines were not finally 
administered were also excluded. A prospective review of the application forms of off-
label drug use and the patients’ electronic medical records was conducted to obtain 
information on patients’ demographic characteristics, morbidity (clinical, biological 
and other complementary explorations), previous and concurrent drug uses for the 
target disease, the requested drug and dosages, the clinical indications and the 
reasons for the requested off-label drug use, and clinical outcomes (effectiveness 
and adverse drug effects). Patients were followed for a period of six months after 
starting off-label drug treatment (or until the end of treatment in cases of an acute 
disease), and the clinical outcomes were assessed by reviewing electronic clinical 
records and interviewing physicians responsible for the patient's care.  
 
Drugs were classified according to the ATC classification, and The International 
Classification of Disease, ninth edition (ICD-9), was used to classify medical 
indication for off-label drug use. Off-label drug use condition was rated as an 
unapproved indication, unapproved condition (population, route or other) or both. The 
reasons for requesting the off-label drug use were categorized as following: lack of 
clinical response to previous treatments, intolerance or contraindications to the 
alternatives  
 
A review of published evidence for every drug use in each clinical indication was 
performed searching for information on the PubMed database. In addition, a search 
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looking at ongoing clinical trials for every drug use in each clinical indication was 
conducted in clinicaltrials.gov register [20]. The Oxford Centre for Evidence Based 
Medicine criteria was used to classify the available evidence found for each 
requested drug in each indication [21]. The level of evidence was pooled into two 
categories: the high level category that included the 1a to 2c categories (mainly 
randomised clinical trials or cohort studies) and the low level that included the 3 to 5 
categories (mainly case-control studies, series of cases, cases and expert opinions). 
 
The clinical responses to off-label use of drugs were classified as complete response 
(CR), partial response (PR), stabilization (S), and no response (NR) taking into 
account different parameters of efficacy for each disease. For example, the criteria 
used in the more common diseases are specified. For botulinum toxin in anal fissure 
the healing of the lesion was considered CR and its persistence without symptoms 
was considered PR. In patients with esophageal achalasia, clinical criteria were also 
used: CR if the patients were able to eat without dysphagia and PR if they felt some 
improvement. CR to omalizumab in chronic urticaria was considered if corticosteroids 
could be withdrawn and the patient was asymptomatic or had minimal symptoms; 
other minor improvements were classified as PR. To assess the response to 
rituximab in patients with organ transplant rejection anatomopathological criteria were 
used, and in pemphigus and myasthenia, clinical criteria were used (resolution was 
considered CR, and improvement PR). In patients with systemic lupus 
erythematosus, the symptoms and scores of disease activity were taken into account 
[CR: Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) of ≤4 or clinical 
remission; PR: improvement of ≥50 % in SLEDAI]. For human unspecific 
immunoglobulins in immune encephalitis clinical criteria (resolution or improvement) 
were considered. 
 
Adverse drug events were assessed by clinical pharmacolgists and/or pharmacists 
trained in using the methods and the algorithm of the Spanish Pharmacovigilance 
System.  
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The actual sale price of medicines paid by participant hospitals   was taken into 
account in the analysis of the cost of treatments. The total cost per patient was 
calculated according to the duration of treatment up to a maximum of 6 months. 
 
The study was conducted in accordance with the international ethics 
recommendations and according to the Spanish post-authorisation studies 
legislation. The study protocol was approved by the ethics committees of clinical 
investigation in each participating hospital. 
 
Statistical analysis of categorical and continuous variables was made by means of 
the distribution of frequencies, proportions, means, standard deviation (SD) and 
median and interquartile range (IQR). Statistical differences were evaluated using the 
chi-square test and the Student's t-test. Significance was set at a level of 0.05 and 
was two-tailed. The statistical analysis was performed using IBM SPSS Statistics 
version 20 statistical package (IBM corp., NY, USA). 
 
Results 
 
A total of 398 requests for treating the corresponding patients were received and 226 
were included in the study (each participating hospital contributed with 85 (37.6%), 
56 (24.8%), 42 (18.6%), 28 (12.4%) and 15 (6.6%) cases respectively). The reasons 
for the exclusions are shown in figure 1. The characteristics of patients treated are 
shown in table 1. The median age (IQR) of treated patients was 46 (33-62) years and 
59% were women. The patients involved had received on average three previous 
treatments for the target diseases, and in 160 cases (70.8%) lack of response to 
previous treatments was the main reason for requesting the off-label drug use. In 
90.3% of cases the requested off-label drugs were for an unapproved indication. 
Clinical services that most frequently requested off-label drug use were 
Gastroenterology, Internal Medicine and Neurology.  
 
A total of 232 off-label medicines were requested and administered to the 226 
patients for 102 different diseases. Two hundred and twenty (97.3%) patients were 
treated with one off-label medicine and 6 (2.7%) with a combination of two medicines. 
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The most frequent pharmacological subgroups were the monoclonal antibodies (in 56 
patients; 24.1%) and other muscle relaxants (25; 10.8%). The most frequent 
medicines were rituximab (49; 21.1%), botulinum toxin (25; 10.7%) and omalizumab 
(14; 6.0%). Rituximab was used in 22 different indications, botulinum toxin in 5 and 
omalizumab in 5 (more details on therapeutic subgroups and medicines is available 
in the annex 1 of the supplementary material). Diseases of the nervous system (31 
patients; 13.7%), neoplasms (30; 13.3%), diseases of the digestive system (29; 
12.8%), and diseases of the skin and subcutaneous tissue (27; 12%) were the most 
frequent conditions. Table 2 shows the most frequent clinical indications in which 
each off-label medicine was used. Botulinum toxin was used to treat 13 (5.6%) 
patients with anal fissure and 8 (3.6%) with achalasia. Rituximab was used to treat 7 
(3%) patients with an acute humoral rejection of a solid organ transplant and 6 (2.6%) 
with pemphigus vulgaris. Omalizumab was used to treat 7 patients (3%) with chronic 
urticaria. 
 
In 117 cases (51.8%) the level of clinical evidence for using the medicines in the 
requested conditions was low, and in 109 (48.2%) was high. The level of evidence 
was 4 in 107 (47.4%) cases, 2b in 48 (21.2%), 1a in 29 (12.8%), 1b in 23 (10.2%), 5 
in 10 (4.4%), 1c and 2a each with 4 (1.8%) and 2c in 1 (0.4%). There were ongoing 
clinical trials assessing the efficacy of off-label medicines in 122 cases (54%), 84 of 
whom on phases III or IV. Table 2 shows the level of clinical evidence and 
information about ongoing clinical trials for each pair of clinical conditions and off-
label medicines.   
 
In 164 (72.6%) patients a clinical response was observed (82 (36.3%) with a partial 
clinical response, 71 (31.4%) with a complete clinical response, and11 (4.9%) with a 
stabilization), in 59 (26.1%) a lack of response, and in 3 (1.3%) it was unknown. 
Patients were concomitantly treated with a median of 2 drugs (IQR 2-4), mainly 
prednisone (77 cases), metilprednisolone (19), immunoglobulins (13), mycophenolate 
mofetil (12), tacrolimus (11) and azatioprine (11). Table 3 shows the clinical response 
to off-label medicines in the different conditions. No statistically significant differences 
were observed  between  patients treated with a medicine with a high level of 
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evidence and those treated with medicines with a low level of evidence (76.9% vs. 
70.4%, respectively, p=0,278).  
 
A total of 58 (25.7%) patients experienced 105 adverse effects. The most frequent 
adverse effects were infections (11 patients; 5.3%), fatigue (11; 4.9%), diarrhoea (9; 
4%), rash and other skin disorders (9; 4%), leukopenia, neutropenia and/or 
lymphopenia (8; 3.5%); nausea and vomiting (5; 2.2%) and thrombocytopenia (5; 
2.2%). Rituximab, erlotinib and bendamustine were the drugs involved in more 
adverse effects. In eleven patients (4.9%) the adverse effects were severe and in 10 
patients this resulted in treatment being withdrawn. In one patient the adverse effect 
(varicella pneumonia with rituximab added to other immunosuppressants in a patient 
with myasthenia gravis) was fatal. 
 
The total cost of off-label medicine treatments was € 997,494.71. The median (IQR) 
cost per patient was € 2,943.07 (541.9 – 5,872.54). The total cost of off-label 
medicine treatments in clinical conditions with some response was € 705,157.35 and 
for those with no response was € 281,626.71. The median cost per patient [IQR] 
without response was higher (€ 4,262.8 [594.55 – 6,770.40]) than that of patients 
with response (€ 2,669.01 [449.7 – 5,463.93]). The total cost of off-label medicines 
with a high level of evidence was € 485.235,89 and for those with a low level was € 
512,258.82. The median cost per patient [IQR] treated with a medicine with a low 
level of clinical evidence was higher (€ 3,085.38 [1,083.76 – 5,046.81]) than that of 
patients treated with a medicine with a high level (€ 2,693.50 [165.48 – 6,552.0]). 
 
Discussion 
Our study shows that a high percentage of patients treated with off-label medicines 
had some response, either complete or partial, despite the fact most of them had 
failed to respond to several previous treatments. However, one out of four treated 
patients had adverse events, and the median cost of off-label treatments was 
relatively high. Although several articles have reported the use of off-label medicines, 
few of them have assessed outcomes in clinical practice, and most have focused on 
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one specific medicine [12, 18]. We believe, this is the first study where the outcomes 
of patients treated with different off-label medicines have been reported. 
It is also interesting to note the wide variety of off-label medicines and indications 
observed in the study. This high variety has been described previously [22]. New 
technological medicines such as biological products were frequently used by patients 
who had severe or life-threatening diseases that had not responded to previous 
treatments. This is not surprising, given that the study was performed in tertiary 
hospitals that have highly specialized services. Biologic medicines are being 
employed more often in clinical practice as off-label treatments in patients with 
autoimmune diseases and severe clinical symptoms [23]. Rituximab was the most 
frequently used off-label medicine as has been reported in other studies [12, 13, 18, 
22]. In addition, rituximab was used in a lot of different diseases because it is an anti-
CD20 monoclonal antibody against B-lymphocytes that can be potentially useful in a 
heterogeneous group of autoimmune and inflammatory diseases. The most frequent 
indications were transplant related and dermatological uses, autoimmune tissue and 
renal diseases. Globally the responses observed with rituximab were high, but the 
partial responses predominated. However, variations in the response were observed. 
In transplant related issues (mainly humoral acute rejection) more patients with a  
complete response were identified. In contrast, more patients  with non-response 
were seen in Idiopathic thrombocytopenic purpura. Other studies have shown similar 
outcomes with off-label use of rituximab [12, 18]. 
Other frequently used medicines were botulinum toxin and omalizumab, but in a 
smaller range of indications. Botulinum toxin was mainly used in anal fissure and 
esophageal achalasia.  The most prevalent response was a complete response in 
both diseases. In a systematic review and meta-analysis, botulinum toxin has been 
similar to glyceryltrinitrate [24] and inferior to the lateral internal sphincterotomy in the 
management of anal fissure [25]. Omalizumab was often used in chronic 
spontaneous urticaria and the responses have been good in most cases. Efficacy of 
omalizumab in symptomatic patients despite H1-antihistamine therapy has been 
shown in a clinical trial [26]. Recently, the Committee for Medicinal Products for 
Human Use (CHMP) from the European Medicines Agency has adopted a positive 
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opinion recommending its use as an add-on therapy to the treatment of chronic 
urticaria [27]. 
In our study, the evidence to use these medicines was often low, as well as the 
frequency of ongoing clinical trials assessing their efficacy. In general, the evidence 
supporting the use of off-label medicines has also been reported as low, although the 
classifications used to rate the evidence have been quite variable [2, 9, 12, 13, 28]. 
Moreover, the level of evidence could be influenced by the health area, period of 
study, kind of medicines and the evaluated indications. Thus, on the one hand, 
Radley et al described that most off-label medicines used in outpatient care had little 
or no scientific support [2]. On the other hand, Mellor et al reported that most off-label 
anticancer medicines are supported by guidelines or published peer-review research 
[9]. Future studies should analyse the variability in the level of evidence of off-label 
medicines according to the different factors mentioned above. 
The most frequent reason for off-label use of medicines was for unapproved 
indications in adults and only a few cases were in children. Our study did not have 
children as a target population, as opposed to other studies [14-17]. In addition, the 
use of off-label medicines was identified through the requests for medicines received 
in pharmacy services. In general, most of these requested medicines are 
sophisticated and expensive, and these types of medicines are less frequently used 
in children especially as off-label use.  
Risk from medicines is often based on studies performed in approved conditions but 
limited data are available on safety in unapproved indications. Moreover, patients’ 
characteristics in unapproved conditions can substantially differ from those of 
approved indications due to the basal disease state and the immunological situation. 
Therefore, in case of off-label medicines use, the benefit-risk relation is even more 
important given the limited available evidence on the efficacy and also safety. Thus, 
data from the Spanish registry BIOBADASER 2.0 showed a higher frequency of 
adverse reactions when TNF-antagonists were used in unapproved rheumatic 
conditions than when they were used in approved rheumatic indications [29]. In 
children, off-label medicines were also more likely to be implicated in an adverse 
drug reaction than authorised medicines [30]. In our study, around one out of four 
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patients had an adverse reaction related to off-label medicines use and some 
reactions were severe or life-threatening. Infections followed by gastrointestinal, 
cutaneous and haematological reactions were the ones most frequently observed. 
These types of reactions are to be expected bearing in mind how the most frequently 
administered medicines work.  
Another important issue in off-label drug uses is the benefit-cost relation. In our study 
the median cost per patient was high because most administered medicines are 
expensive. However, other studies have shown that the cost of treatment with 
medicines is higher when they are used for non-approved conditions than for 
approved indications [31]. Interestingly, in our study the median cost per patient 
without response was higher than that of a patient with response, although the 
difference was not statistically significant. Further studies should analyse the cost of 
off-label use of medicines compared to the outcomes.  
In our study different medicines were administered for off-label use for a diverse 
range of clinical conditions and often with a low level of available evidence. 
Randomized clinical trials should be performed in these conditions but problems in 
financing and recruiting patients who have rare diseases may make it difficult to 
conduct them. Alternatively, national or international registers of patients treated with 
off-label medicines may be useful as a source of information on their effectiveness 
and safety. In any case, use of these medicines requires a careful assessment of 
each case and a sensible expectation in relation to clinical outcomes. Le Jeunne et al 
proposed a control system for all off-label prescriptions with a dedicated committee 
which would determine the frame of off-label prescriptions, in order to improve the 
use of these medicines [32]. 
Our study has several limitations. Firstly, we did an observational study without a 
control group of patients and, hence, some biased results could be present in the 
assessment of clinical outcomes. Secondly, we included a heterogeneous range of 
diseases and medicines, with few cases in each group followed for a short period of 
time, and this hinders the analysis and interpretation of results. Thirdly, our study was 
based on the requests for off-label uses, and this can limit the validity of the study 
results. Fourly, the study was performed in five tertiary hospitals in our area, and this 
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limits the extrapolation of results to other hospitals with different characteristics or 
geographic areas. Nevertheless, the main strength of our study is the assessment of 
clinical outcomes in different off-label medicines use. Moreover, we have done a 
multicentric study in large tertiary university hospitals that cover most medical and 
surgical specialities to a high level of complexity. 
In conclusion, in our study a high variability of off-label medicines and indications was 
found. Although the clinical evidence of off-label medicines was often low, a high 
percentage of some clinical responses in patients with previous multiple treatment 
failures was observed. However, this was at the expenses of adverse effects (some 
of them severe) and a high cost. Even though more evidence from clinical trials 
would be desirable, they can be difficult to carry out and finance especially where 
rare diseases are concerned. Meanwhile, data from observational studies and 
registers of patients treated with off-label medicines should be kept to obtain 
information and to assist in prescribing decisions in clinical practice. 
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Table 1. Clinical characteristics of patients and requests. 
Characteristics Patients (N=226) 
Age (median, IQR) years 
  < 18 years (%) 
  18-64 years (%) 
  ≥65 years (%) 
46 (33-62) 
28 (12.4) 
147 (65.0) 
51 (22.6) 
Gender (%) 
  Female 
  Male 
 
133 (59) 
93 (41) 
  Arterial hypertension (%) 
  Hyperlipidemia (%) 
  Diabetes (%) 
  Chronic renal failure (%) 
  Coronary heart disease 
  Heart failure (%)  
   
58 (25.7) 
32 (14.2) 
25 (11.1) 
14 (6.2) 
13 (5.7) 
3 (1.3)  
 
Previous treatments for the target diseases (median, IQR) 3 (2-5) 
Clinical services (%) 
  Gastroenterology 
  Internal medicine 
  Neurology 
  Oncology 
  Allergy 
  Nephrology 
  Haematology 
  Dermatology 
  Othersa 
 
33 (14.6) 
30 (13.3) 
28 (12.4) 
14 (6.2) 
14 (6.2) 
13 (5.8) 
13 (5.8) 
12 (5.3) 
69 (30.4) 
Off-label drug use condition (%) 
  Unapproved indication 
  Unapproved condition  
  Unapproved indication and condition 
 
204 (90.3) 
10 (4.4) 
12 (5.3) 
Reasons for off-label drug use (%)b Lack of clinical response to the previous 
treatments 
  No other drugs approved for that indication/condition 
  Intolerance to the previous treatments 
  Preferred to the alternative drugs for that patient (logistical reasons) 
  Contraindications to the alternatives 
  Preferred to the alternative drugs for that condition 
  Suboptimal response to previous treatments 
 
160 (70.8) 
28 (12.4) 
26 (11.5) 
12 (5.3) 
10 (4.4) 
8 (3.5) 
3 (1.3) 
 
a Paediatrics (9), Pneumology (9), Rheumatology (9), Otorhinolaryngology (6), Ophthalmology (4), Intensive Care 
Medicine (4), Thoracic Surgery (4), Gastrointestinal Surgery (3),  Paediatric Cardiology (3), Paediatric Nephrology 
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(3), Vascular Surgery (2), Paediatric Infectious Diseases (2), Paediatric Oncology (2), and other services with only 
one case (9). 
b More than one reason per patient was possible.
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Table 2. Level of evidence-based of most frequently used medicines in each indicationa. 
Medicine Indication N (%) Level of 
evidence 
Ongoing clinical 
trial 
Complications of organ or tissue transplant, failure 
or rejection 
7 (3.0) 4 Phase III 
Pemphigus 6 (2.6) 4 Phase III 
Myasthenia gravis 4 (1.7) 4 Phase II 
Systemic lupus erythematosus (SLE) 4 (1.7) 2b - 
Cryoglobulinemic purpura 3 (1.3) 2b Phase II 
Lupus nephritis 3 (1.3) 2b - 
Wegener granulomatosis 3 (1.3) 1b Phase III 
Encephalitis, myelitis and encephalomyelitis 2 (0.8) 4 - 
Glomerulonefritis, membranous 2 (0.8) 4 Phase III 
Idiopathic thrombocytopenic purpura  2 (0.8) 1b Phase III 
Relapsing polychondritis  2 (0.8) 4 - 
Glomerulonephritis, minimal change disease  1 (0.4) 2b Phase III 
Graft-versus-host disease 1 (0.4) 2a Phase II 
Lymphoproliferative disorder 1 (0.4) 2b  - 
Neuromyelitis optica 1 (0.4) 4 Phase I 
Polymyositis 1 (0.4) 4 - 
Polyradiculoneuropathy, chronic inflammatory 
demyelinating 
1 (0.4) 4 - 
Sarcoidosis 1 (0.4) 4 Phase II 
Sjögren syndrome 1 (0.4) 2b Phase II 
Systemic scleroderma 1 (0.4) 2b Phase II 
Thrombocytopenia in SLE 1 (0.4) 4 - 
Waldenström macroglobulinaemia 1 (0.4) 2b Phase II 
Rituximab 
                                          Subtotal 49 (21.1)   
Anal fissure 13 (5.6) 1a Phase IV 
Esophageal achalasia 8 (3.4) 1a - 
Generalized hyperhidrosis 2 (0.8) 1a Phase IV 
Eyelid retraction 1 (0.4) 2b Phase IV 
Myofascial pain 1 (0.4) 2b Phase IV 
Botulinum toxin 
                                          Subtotal 25 (10.8)   
Chronic urticaria 7 (3.0) 2b Phase III 
Food-induced anaphylaxis  3 (1.3) 4 Phase II 
Cold-induced urticaria 2 (0.8) 4 - 
Extrinsic allergic asthma 1 (0.4) 4 Phase IV 
Nasal polyps 1 (0.4) 4 Phase IV 
Omalizumab 
                                          Subtotal 14 (6.0)   
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a
 Information about the other used medicines is available in annex 2 of supplementary material.   
b Level 4 in one case with rituximab. 
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Table 3. Outcomes for the most frequently used medicines in each indicationa  
 Complete 
response 
N  
Partial 
response 
N  
Stabilization 
N  
No 
response 
N  
Total 
N  
Rituximab 
     
Complications of organ or tissue transplant, 
failure or rejection 3  2  - 2  7  
Pemphigus 1  4   1  6  
Myasthenia gravis 2  - 1  1  4  
Systemic lupus erythematosus (SLE) 0 2  - 2  4)  
Cryoglobulinemic purpura 2  1  - - 3  
Lupus nephritis 1  1  - 1 3  
Wegener granulomatosis - 3  - - 3 
Encephalitis, myelitis and encephalomyelitis - 1  - 1  2  
Glomerulonephritis, membranous - 1  - 1  2  
Idiopathic thrombocytopenic purpura     2  2  
Relapsing polychondritis - - - 2  2  
Glomerulonephritis, minimal change disease  1  - - - 1  
Graft-versus-host disease - 1 - - 1  
Lymphoproliferative disorder 1  - - - 1  
Neuromyelitis optica - 1  - - 1  
Polymyositis 1  - - - 1  
Polyradiculoneuropathy, chronic inflammatory 
demyelinating 
- 1  - - 1  
Sarcoidosis - - - 1  1  
Sjögren syndrome - 1  - - 1  
Systemic sclerodermia - - 1  - 1  
Thrombocytopenia in SLE 1     1  
Waldenström macroglobulinaemia - 1  - - 1  
                                         Subtotal (%) 13 (26.5) 20 (40.8) 2 (4.1) 14 (28.6) 49 (100) 
Botulinum toxin 
     
Anal fissure 6  4  - 3  13  
Esophageal achalasia 6  1  - - 7 b 
Generalized hyperhidrosis - 1  - 1  2  
Eyelid retraction 1  - - - 1  
Myofascial pain - 1  - - 1  
                                          Subtotal  (%) 13 (54.2) 7 (29.1) - 4 (16.7) 24 (100)b 
Omalizumab 
     
Chronic urticaria 5  1  - 1  7  
Food-induced anaphylaxia  2  - - 1  3  
Cold-induced urticaria - 2  - - 2  
Extrinsic allergic asthma - 1  - - 1  
Nasal polyps 1  - - - 1  
                                          Subtotal (%) 8 (57.1) 4 (28.6) - 2 (14.3) 14 (100) 
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a 
 Information about the other used medicines is available in  annex 3 of supplementary material.   
b One unknown response. 
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Figure 1. Flowchart of the included patients in the study 
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• Non-marketed medicines in 
Spain (64) 
• Compassionate use of 
investigational medicines (18) 
• 32 cases non-authorized by 
Health care Managers  
• 31 cases without the informed 
consent of patients  
• 27 cases without administration 
of medicines 
226 
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